Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

2.

The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.

Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL.

Ann Rheum Dis. 2007 Nov;66(11):1473-8. Epub 2007 Apr 10. Review.

3.

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.

Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A.

BMC Musculoskelet Disord. 2008 Apr 17;9:52. doi: 10.1186/1471-2474-9-52. Review.

4.

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.

Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T.

Scand J Rheumatol. 2007 Nov-Dec;36(6):411-7. Review.

PMID:
18092260
5.

Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.

Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R.

Pharmacotherapy. 2010 Apr;30(4):339-53. doi: 10.1592/phco.30.4.339. Review.

PMID:
20334454
6.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

7.

Adalimumab: a review of its use in rheumatoid arthritis.

Bang LM, Keating GM.

BioDrugs. 2004;18(2):121-39. Review.

PMID:
15046527
8.

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP.

Pharmacoeconomics. 2012 Jul 1;30(7):575-93. doi: 10.2165/11594990-000000000-00000. Review. Erratum in: Pharmacoeconomics. 2012 Nov 1;30(11):1096.

PMID:
22640174
9.

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.

Keating GM, Perry CM.

BioDrugs. 2002;16(2):111-48. Review.

PMID:
11985485
10.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

11.
12.

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.

Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M.

PLoS One. 2012;7(1):e30275. doi: 10.1371/journal.pone.0030275. Epub 2012 Jan 17. Review.

13.

Indirect comparison of biological treatments in refractory rheumatoid arthritis.

Gallego-Galisteo M, Villa-Rubio A, Alegre-del Rey E, Márquez-Fernández E, Ramos-Báez JJ.

J Clin Pharm Ther. 2012 Jun;37(3):301-7. doi: 10.1111/j.1365-2710.2011.01292.x. Epub 2011 Aug 10. Review.

PMID:
21831256
14.
15.

Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.

Richard-Miceli C, Dougados M.

BioDrugs. 2001;15(4):251-9. Review.

PMID:
11437690
16.
17.

Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.

Moreland LW.

Pharmacoeconomics. 2004;22(2 Suppl 1):39-53. Review. Erratum in: Pharmacoeconomics. 2004;22(8):547.

PMID:
15157003
18.

[New drugs and treatment strategies for rheumatoid arthritis].

Fantini F.

Recenti Prog Med. 2003 Sep;94(9):361-79. Review. Italian.

PMID:
12942798
19.

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM.

Clin Ther. 2008 Nov;30(11):1939-55. doi: 10.1016/j.clinthera.2008.11.007. Review.

PMID:
19108784
20.

[The role of biological agents in the treatment of psoriatic arthritis, literature review].

Koó E, Brodszky V, Péntek M, Ujfalussy I, Nagy MB, Gulácsi L.

Orv Hetil. 2006 Oct 15;147(41):1963-70. Review. Hungarian.

PMID:
17120686

Supplemental Content

Support Center